UV1 Vaccine Plus Pembrolizumab Shows Strong Safety, Early Activity in Metastatic Melanoma

Source: OncLive, September 2021

The universal cancer vaccine UV1 and granulocyte-macrophage colony-stimulating factor (GM-CSF) in combination with pembrolizumab (Keytruda) elicited encouraging initial signs of clinical response with favorable safety and tolerability when used in the first-line treatment of patients with metastatic melanoma, meeting the primary end point of an ongoing phase 1 trial (NCT03538314).1

READ THE ORIGINAL FULL ARTICLE

 

Menu